Post-trial access to study medication: A brazilian e-survey with major stakeholders in clinical research

Journal of Medical Ethics

Volumn 38, Issue 12, 2012, Pages 757-762

  Dainesi, Sonia M ^a   Goldbaum, Moises ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BRAZIL; CLINICAL TRIAL (TOPIC); DRUG INDUSTRY; ECONOMICS; ETHICS; FINANCIAL MANAGEMENT; HEALTH CARE DELIVERY; HUMAN; METHODOLOGY; PERSONNEL; PROFESSIONAL STANDARD; QUESTIONNAIRE; RESEARCH SUBJECT; STATISTICS;

BRAZIL; CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; ETHICS COMMITTEES, RESEARCH; HEALTH SERVICES ACCESSIBILITY; HUMANS; QUESTIONNAIRES; RESEARCH DESIGN; RESEARCH PERSONNEL; RESEARCH SUBJECTS; RESEARCH SUPPORT AS TOPIC;

EID: 84872274089     PISSN: 03066800     EISSN: 14734257     Source Type: Journal    
DOI: 10.1136/medethics-2011-100127     Document Type: Article

References (31)

1. Thiers F, Sinskey AJ, Berndt ER. Trends in the globalization of clinical trials. Nature Reviews. Drug Discovery 2008;7:13-14.
2. Rodrigues D, Kesselring G. Clinical trials in Brazil. Facing the challenges. Monitor 2008;75-7.
3. Glickman SW, McHutchison JG, Peterson ED, et al. Ethical and scientific implications of the globalization of clinical research. N Engl J Med 2009;360
4. Mano MS, Rosa DD, Lago LD. Multinational clinical trials in oncology and post-trial benefits for host countries where do we stand? Eur J Cancer 2006;42:2675-7
5. Petryna A. When experiments travel: clinical trials and the global search for human subjects. Princeton and Oxford: Princeton University Press, 2009.
6. Grady C. The challenge of assuring continued post-trial access to beneficial treatment. Yale J Health Policy Law and Ethics 2005;1:425-35.
7. Merritt M, Grady C. Reciprocity and post-trial access for participants in antiretroviral therapy trials. AIDS 2006;20:1791-4.
8. Schlemper-Junior BR. Acesso às drogas na pesquisa clínica. Revista Bieótica 2007;15:248-66.
9. Schroeder D. Obrigações pós-pesquisa. RECIIS-Rev Eletr Comum Inform Inov Saúde 2008;2(Sup1):S66-77.
10. WMA. Declaration of Helsinki. (cited 02 Dec 2011). http://www.wma.net/en/ 30publications/10policies/b3/index.html
11. Council for International Organizations of Medical Sciences (CIOMS), in collaboration with the World Health Organization (WHO). International Ethical Guidelines for Biomedical Research Involving Human Subjects. CIOMS, Geneva 2002. (cited 29 Nov 2011). http://www.cioms.ch/publications/layout_guide2002.pdf
12. Shaffer DN, Yebei VN, Ballidawa JB, et al. Equitable treatment for HIV/AIDFS clinical trials participants: a focus group study of patients, clinician researchers and administrators in western Kenya. J Med Ethics 2006;32:55-60.
13. Millum J. Post-trial access to antiretrovirals. Bioethics 2011;25:145-54.
14. Sofaer N, Strech D. Reasons why post-trial access to trial drugs should, or need not be ensured to research participants: a systematic review. Public Health Ethics 2011;4:160-84.
15. Lavery JV. The obligation to ensure access to beneficial treatments for research participants at the conclusion of clinical trials. In: Emanuel EJ, Grady C, Crouch RA, Lie RK, Miller FG, Wendler D, eds. The oxford textbook of clinical research ethics. New York: Oxford University Press, 2008:697-710.
16. Ashcroft R. Science and development network. Policy briefs. May 1st, 2005. After the trial is over: What are the sponsor's obligations? (cited 30 Nov 2011). http:// www.scidev.net/en/policy-briefs/after-the-trial-is-over-what-are-the-sponsor-s-obl. html
17. Kass N, Hyder A. Attitudes and experiences of U.S. and developing country investigators regarding U.S. human subjects regulations. In: National Bioethics Advisory Commission Group, ed. Ethical and policy issues in international research: clinical trials in developing countries II: commissioned papers. Vol. 2. Bethesda, Maryland: National Bioethics Advisory Commission, 2002:B1-220.
18. Sofaer N, Thiessen C, Goold SD, et al. Subjects' views of obligations to ensure post-trial access to drugs, care and information: qualitative results from the Experiences of Participants in Clinical Trials (EPIC) study. J Med Ethics 2009;35:183-8.
19. Zong Z. Should post-trial provision of beneficial experimental interventions be mandatory in developing countries? J Med Ethics 2008;34:188-92.
20. Pace C, Grady C, Wendler D, et al., for the ESPRIT Group. Post-trial access to tested interventions: the views of IRB/REC chair, investigators, and research participants in a multinational HIV/AIDS study. AIDS Res and Human Retroviruses 2006;22:837-41.
21. Deucher KLAL. Análise da justiça distributiva no fornecimento de medicações após estudos clínicos no Brasil. (dissertação). São Paulo: Faculdade de Saúde Pública, Universidade de São Paulo, 2009.
22. Dainesi SM. Fornecimento de medicamento pós-pesquisa. (tese). São Paulo: Faculdade de Medicina da Universidade de São Paulo, 2011. (cited 30 Nov 2011). http://www.teses.usp.br/teses/disponiveis/5/5137/tde-17062011-154214/pt-br.php
23. ABRACRO-Brazilian Association of Clinical Research Organizations Guarantee of access to post-clinical trial drugs. (cited 2 Nov 2011). http://abracro.org.br/en/informacoes-a-utilidades/artigos/todos-os-artigos/40-pesquisa-clinica/133-garantia-de-acesso-a-medicamentos-pos-estudos-clinicos
24. Cohen ERM, O'neill JM, Joffres M, et al. Reporting of informed consent, standard of care and post-trial obligations in global randomized intervention trials: a systematic survey of registered trials. Devel World Bioethics 2008;1471-8731(print); 1471-8847(online).
25. Sabik L, Pace CA, Forster-Gertner HP, et al. Informed consent: practices and views of investigators in a multinational clinical trial IRB: Ethics and Human Research 2005;27:13-18.
26. Lacativa PGS, Szrajbman M, Silva DASM, et al. Perfil de sujeitos de pesquisa clínica em um centro ambulatorial independente. Ciência e Saúde Coletiva 2008;13:611-20.
27. Eysenbach G. Improving the Quality of Web Surveys: The Checklist for Reporting Results of Internet E-Surveys (CHERRIES). J Med Internet Res 2004;6:e34.
28. Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344-9.
29. Shah S, Elmer S, Grady C. Planning for posttrial access to antiretroviral treatment for research participants in developing countries. Amer J of Public Health 2009;99:1556-62.
30. Zammar G, Meister H, Shah J, et al. So different, yet so similar: meta-analysis and policy modeling of willingness to participate in clinical trials among Brazilians and Indians. PLoS One 2010;5:e14368.
31. Casarett D, Karlawish J, Sankar P, et al. Open label extension studies & the ethical design of clinical trials. Hasting Center Report 2001;23:1-5.